1. Home
  2. BBNX vs LYEL Comparison

BBNX vs LYEL Comparison

Compare BBNX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$11.57

Market Cap

555.7M

Sector

Health Care

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$23.84

Market Cap

490.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBNX
LYEL
Founded
2015
2018
Country
United States
United States
Employees
423
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
555.7M
490.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BBNX
LYEL
Price
$11.57
$23.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
3
Target Price
$26.73
$25.00
AVG Volume (30 Days)
1.2M
95.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$61,000.00
Revenue This Year
$35.03
N/A
Revenue Next Year
$33.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.89
$0.39
52 Week High
$32.71
$45.00

Technical Indicators

Market Signals
Indicator
BBNX
LYEL
Relative Strength Index (RSI) 25.10 48.77
Support Level N/A $21.27
Resistance Level $15.53 $27.30
Average True Range (ATR) 0.95 2.19
MACD 0.17 0.14
Stochastic Oscillator 2.05 50.22

Price Performance

Historical Comparison
BBNX
LYEL

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Share on Social Networks: